Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Related AGN
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology
Allergan to Slash 13% of its Global Workforce (Fox Business)
Related VRX
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
Yellen's Speech Not Enough To Keep Dow, S&P 500 In Positive Territory
Allergan Rebuffs Valeant's Tender Offer (Fox Business)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters